Table 3 In-field tumor response rates of the target lesions after tomotherapy and concurrent capecitabine treatment
From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
Target lesions | CR | PR | SD | PD |
|---|---|---|---|---|
Pancreatic mass (n = 15) | 0 (0) | 8 (53.3) | 7 (46.7) | 0 (0) |
Regional lymph nodes (n = 4) | 0 (0) | 1 (25.0) | 3 (75) | 0 (0) |
Distant metastasis (n = 7) | 0 (0) | 2 (28.6) | 5 (71.4) | 0 (0) |
Liver (n = 6) | 0 (0) | 1 (16.7) | 5 (83.3) | 0 (0) |
Lung (n = 1) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
Overall (n = 26) | 0 (0) | 11 (42.3) | 15 (57.7) | 0 (0) |